The Journal of Microbiology · 2010 · 21 citations · 13 references
Life SciencesInfectious DiseasesMicrobiologyMedical MicrobiologyMicrobial PathogenesisMycologyAntifungal AgentsAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyFungal InfectionsFungal PathogenesisAntifungal TreatmentsCandida TherapyCandida-host InteractionsCandidiasis Drug ResistanceConcentrationIn Vivo StudiesTreatment Of Oral Candidiasis
We investigated the activity of caspofungin against a Candida tropicalis clinical isolate showing paradoxical growth in vitro. BALB/c mice immunosuppressed by cyclophosphamide were infected intraperitoneally using 10(7) CFU/mouse. Caspofungin was administered intraperitoneally once daily for 5 days or as a single dose using the following doses: 0.12, 0.25, 1, 2, 3, 5, and 15 mg/kg. The single dose of caspofungin was effective only at 5 and 15 mg/kg concentrations (100% survival). Five-day caspofungin treatment led to 100% survival at doses of 1 mg/kg or higher. Caspofungin treatment significantly decreased the number of viable yeasts in the peritoneal lavage samples as well as in the infected abscesses at doses 1, 3, 5, and 15 mg/kg caspofungin as compared to the untreated control (P<0.001 in all cases), and even to the group treated with 0.12 mg/kg caspofungin (P<0.05 in all cases). At 2 mg/kg caspofungin dose, sterilization of the internal organs was reproducibly incomplete, suggesting that the role of paradoxical growth in the late clinical failure cannot be excluded.
13
Louis D. Saravolatz, Stanley C. Deresinski, David A. Stevens · Clinical Infectious Diseases · 2003 · 293 citations · Full text
Robert F. Betts, Márcio Nucci, Deepak Talwar et al. · Clinical Infectious Diseases · 2009 · 213 citations · Full text
Nathan P. Wiederhold, Dimitrios P. Kontoyiannis, Jingduan Chi et al. · The Journal of Infectious Diseases · 2004 · 206 citations